GBL-Containing Supplements Should Be Recalled - FDA "Talk Paper"
This article was originally published in The Tan Sheet
Executive Summary
FDA will proceed with regulatory action, such as a warning letter, against gamma butyrolactone (GBL) dietary supplement producers if they do not respond to an agency request for the companies to voluntarily recall their products. The agency suggested the voluntary recall in a Jan. 21 "Talk Paper."
You may also be interested in...
Tiratricol Use Warning, Recall Alert Subject Of FDA "Talk Paper"
FDA is cautioning consumers for a second time against using products containing tiratricol. In a "Talk Paper" issued Nov. 21, the agency cites a series of new recalls, three involving two unapproved new drugs and another relating to an improperly labeled dietary supplement.
Tiratricol Use Warning, Recall Alert Subject Of FDA "Talk Paper"
FDA is cautioning consumers for a second time against using products containing tiratricol. In a "Talk Paper" issued Nov. 21, the agency cites a series of new recalls, three involving two unapproved new drugs and another relating to an improperly labeled dietary supplement.
Tiratricol Use Warning, Recall Alert Subject Of FDA "Talk Paper"
FDA is cautioning consumers for a second time against using products containing tiratricol. In a "Talk Paper" issued Nov. 21, the agency cites a series of new recalls, three involving two unapproved new drugs and another relating to an improperly labeled dietary supplement.